Are you Dr. Herbolsheimer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
110 Irving St Nw
Washington, DC 20010Phone+1 202-877-7000
Summary
- Dr. Pia Herbolsheimer, MD is an oncologist in Washington, District of Columbia. She is currently licensed to practice medicine in District of Columbia and Maryland. She is affiliated with MedStar Washington Hospital Center and is an Assistant Professor at Georgetown Univ Sch of Med.
Education & Training
- MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2004 - 2007
Certifications & Licensure
- DC State Medical License 2007 - 2016
- MD State Medical License 2011 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013-2014
Clinical Trials
- Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Start of enrollment: 2011 Apr 01
Publications & Presentations
PubMed
- 19 citationsLong-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compr...Katia E. Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau T. Dang
Breast Cancer Research and Treatment. 2021-01-05 - 15 citationsOlaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.Matthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, Maja De Jonge, Sang-We Kim
Lung Cancer. 2023-06-01 - 243 citationsOlaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Susan M. Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean Pierre Delord
The Lancet. Oncology. 2020-09-01